10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2019 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 21, 2020) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 3,687 | 2,368 | 477 |
| Adjustments to reconcile net earnings to net cash from operating activities - | |||
| Depreciation | 1,078 | 1,100 | 1,046 |
| Amortization of intangible assets | 1,936 | 2,178 | 1,975 |
| Share-based compensation | 519 | 477 | 406 |
| Amortization of inventory step-up | 32 | 907 | |
| Investing and financing losses, net | 184 | 126 | 47 |
| Loss on extinguishment of debt | 63 | 167 | |
| Amortization of bridge financing fees | 5 | ||
| Gains on sale of businesses | (1,163) | ||
| Gain on sale of Mylan N.V. shares | (45) | ||
| Trade receivables | (275) | (190) | (207) |
| Inventories | (593) | (514) | 249 |
| Prepaid expenses and other assets | (138) | 23 | 109 |
| Trade accounts payable and other liabilities | 220 | 747 | 615 |
| Income taxes | (545) | (214) | 1,149 |
| Net Cash From Operating Activities | 6,136 | 6,300 | 5,570 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,638) | (1,394) | (1,135) |
| Acquisitions of businesses and technologies, net of cash acquired | (170) | (54) | (17,183) |
| Proceeds from business dispositions | 48 | 48 | 6,042 |
| Proceeds from the sale of Mylan N.V. shares | 2,704 | ||
| Purchases of investment securities | (103) | (131) | (210) |
| Proceeds from sales of investment securities | 21 | 73 | 129 |
| Other | 27 | 102 | 35 |
| Net Cash From (Used in) Investing Activities | (1,815) | (1,356) | (9,618) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | (26) | (1,034) | |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 1,842 | 4,009 | 6,742 |
| Repayments of long-term debt and debt with maturities over 3 months | (3,441) | (12,433) | (8,650) |
| Purchase of Alere preferred stock | (710) | ||
| Acquisition and contingent consideration payments related to business acquisitions | (13) | ||
| Purchases of common shares | (718) | (238) | (117) |
| Proceeds from stock options exercised | 298 | 271 | 350 |
| Dividends paid | (2,270) | (1,974) | (1,849) |
| Net Cash From (Used in) Financing Activities | (4,289) | (10,391) | (5,281) |
| Effect of exchange rate changes on cash and cash equivalents | (16) | (116) | 116 |
| Net (Decrease) Increase in Cash and Cash Equivalents | 16 | (5,563) | (9,213) |
| Cash and Cash Equivalents, Beginning of Year | 3,844 | 9,407 | |
| Cash and Cash Equivalents, End of Year | 3,860 | 3,844 | 9,407 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 930 | 740 | 570 |
| Interest paid | 677 | 845 | 917 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2019 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |